Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab for Operable Esophageal Squamous Cell Carcinoma
NCT03987815Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Aug 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Samsung Medical Center. Primary endpoint: Major Pathologic Response at 2 months. Status: unknown.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03987815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987815.